| Friday, November 2 |
| 7:50 am - 8:00 am |
President's Welcome
Jon M. Wigginton, MD - Merck & Co., Inc. |
| 8:00 am - 8:45 am |
Richard V. Smalley Memorial Lectureship
Interferons (IFNs) for Cancer: Defining Biological Response
Modification and
Full Therapeutic Potential
 Ernest C. Borden, MD - Cleveland Clinic Foundation |
| 8:45 am - 11:30 am |
Plenary Session: Cellular Therapies
Co-Chairs:
Michel Sadelain, MD, PhD - Memorial Sloan-Kettering Cancer Center
James C. Yang, MD - National Cancer Institute
|
| 8:45 am - 9:15 am |
Adoptive Cellular Therapy: Sustained Regression of Large Tumor Burdens with In Vitro Expanded T-Cells
James C. Yang, MD - National Cancer Institute
|
| 9:15 am - 9:45 am |
Targeting Tumors with Genetically Enhanced T Lymphocytes
Michel Sadelain, MD, PhD - Memorial Sloan-Kettering Cancer Center
|
| 9:45 am - 10:15 am |
Engineering Cytolytic Effector Cells for Glioma Immunotherapy
Using Gene Insertion and Zinc Finger Nuclease Genomic Editing
Michael C.V. Jensen, MD - City of Hope / Beckman Research Institute
|
| 10:45 am - 11:00 am |
A Comprehensive Platform for T Cell Expansion Based on
Biodegradable Artificial Antigen-Presenting Microparticulates
Tarek Fahmy, PhD - Yale University
|
| 11:00 am - 11:15 am |
Tumor-Specific CD4 T Cells are Required for Long-Term Anti-Tumor
Immunity in Reconstituted Lymphopenic Animals
Kevin Friedman, PhD - Earle A. Chiles Research Institute
|
| 11:15 am - 11:30 am |
T-Cell Therapy for the Control of EBV-Related Nasopharyngeal Carcinoma
Paulo Pedrazzoli, MD - Ospedale Niguarda Ca’ Granda
|
| 1:30 pm - 3:30 pm |
Plenary Session: Characterizing the Host Response to Cancer
Co-Chairs:
George Coukos, MD, PhD - University of Pennsylvania Medical Center
Thomas F. Gajewski, MD, PhD - University of Chicago
|
| 1:30 pm - 2:00 pm |
Stat3 Mediates a Crosstalk Between Tumor Cells and Immune Cells
in the Tumor Microenvironment
Hua Yu, PhD - City of Hope National Medical Center
|
| 2:00 pm - 2:15 pm |
Antibody Immunity to a Panel of Oncogenic Proteins May Predict
Presence of Colon Cancer and Stage of Disease
Vivian Goodell, MPH - University of Washington
|
| 2:15 pm - 2:30 pm |
A Possible Role for Regulatory T-Cells in Survival Differences Between Helicobacter Pylori Posititve and Negative Gastric
Cancer Patients After Curative Tumor Resection
Hauke Winter, MD - Klinikum Grosshadern, Ludwig-Maximilians University of Munich
|
| 2:30 pm - 2:45 pm |
Immunophenotypic Analysis of Melanoma Metastases: A New Approach for Prognostication in Stage IV Melanoma
Alicia M. Terando, MD - John Wayne Cancer Institute
|
| 2:45 pm - 3:00 pm |
A Cell-Based Vaccine for Neuroblastoma Induces VLA-2 (CD49b) on
CD8+ T Effector/Memory Cells Via CD137
Rimas J. Orentas, PhD - Medical College of Wisconsin
|
| 3:00 pm - 3:30 pm |
Endothelin (B) Receptor Mediates the Endothelial Barrier to T-Cell Homing to Tumors, and Its Neutralization Enables Tumor
Immune Therapy
George Coukos, MD, PhD - University of Pennsylvania Medical Center
|
| 3:45 pm - 5:15 pm |
Concurrent Session I: Cytokines
Co-Chairs:
Michael T. Lotze, MD - University of Pittsburgh
Crystal Mackall, MD - National Cancer Institute
|
| 3:45 pm - 4:15 pm |
Interleukin 1 Family Members Regulate Tumor Immunity in Response
to Damage Associated Molecular Pattern Molecules (DAMPs)
Michael T. Lotze, MD - University of Pittsburgh Cancer Institute
|
| 4:15 pm - 4:30 pm |
IL-24 and Its Role in Wound Healing
Nancy J. Poindexter, PhD - MD Anderson Cancer Center
|
| 4:30 pm - 4:45 pm |
Intra-Tumoral IL-12 Promotes CD8 + T-Effector/Memory Cell-
Mediated IFN-Gamma and FASL-Dependent Elimination of CD4+ CD25+
FOX3+ T-Suppressor Cells from Tumors
Mehmet O. Kilinc, PhD - University at Buffalo / SUNY
|
| 4:45 pm - 5:15 pm |
Interleukin-7 Therapy in Humans: Proof-of-Principle
Crystal Mackall, MD - National Cancer Institute, Pediatric Oncology
|
| 3:45 pm - 5:15 pm |
Concurrent Session II: Angiogenesis and Vascular Therapies
Co-Chairs:
Luigi Naldini, PhD - San Raffaele Telethon Institute for Gene Therapy
Renata Pasqualini, PhD - MD Anderson Cancer Center
|
| 3:45 pm - 3:50 pm |
Introduction
Renata Pasqualini, PhD - MD Anderson Cancer Center
|
| 3:50 pm - 4:25 pm |
Ligand-Directed Targeting and Molecular Genetic Imaging in
Diseases with an Angiogenesis Component
Wadih Arap, MD, PhD - MD Anderson Cancer Center
|
| 4:25 pm - 5:00 pm |
Tie2-Expressing Monocytes: a Novel Lineage of Proangiogenic Cells
Luigi Naldini, PhD - San Raffaele Telethon Institute for Gene Therapy
|
| 5:00 pm - 5:15 pm |
Impaired Angiogenesis in Aminopeptidase N-Null Mice
Roberto Rangel, PhD - MD Anderson Cancer Center
|
